<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2C8CD331-4C2E-499A-AFD3-3A16680EBC93"><gtr:id>2C8CD331-4C2E-499A-AFD3-3A16680EBC93</gtr:id><gtr:name>SimPore Inc</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EED55AEE-EE68-4B5D-BB08-C4F173080300"><gtr:id>EED55AEE-EE68-4B5D-BB08-C4F173080300</gtr:id><gtr:name>Alliance Boots</gtr:name><gtr:address><gtr:line1>D122 Records Centre</gtr:line1><gtr:postCode>NG90 4XY</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318"><gtr:id>5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318</gtr:id><gtr:name>Astex Pharmaceuticals</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/00EC857A-A759-4CBA-B69D-4699F33CBC26"><gtr:id>00EC857A-A759-4CBA-B69D-4699F33CBC26</gtr:id><gtr:name>Oxtex Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3CFB9490-9508-4E43-A019-042327F992A7"><gtr:id>3CFB9490-9508-4E43-A019-042327F992A7</gtr:id><gtr:name>Eisai Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/96BFFAB5-69B1-49E8-8F41-9C763818EFA6"><gtr:id>96BFFAB5-69B1-49E8-8F41-9C763818EFA6</gtr:id><gtr:name>Jaguar Land Rover</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E7A3C64A-4899-4B20-ABFA-E49DC0E6441E"><gtr:id>E7A3C64A-4899-4B20-ABFA-E49DC0E6441E</gtr:id><gtr:name>Sygnature Discovery Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4A53D269-02C1-473C-BEB5-28B220F178AF"><gtr:id>4A53D269-02C1-473C-BEB5-28B220F178AF</gtr:id><gtr:name>Crown Bioscience Inc.</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8A621CD6-4DE9-4B35-992C-631871D7793E"><gtr:id>8A621CD6-4DE9-4B35-992C-631871D7793E</gtr:id><gtr:name>University of Rochester</gtr:name><gtr:address><gtr:line1>PO Box 270001</gtr:line1><gtr:line4>Rochester</gtr:line4><gtr:line5>New York</gtr:line5><gtr:postCode>NY 14627</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE3B711-DED5-4EB0-AC1A-EE27FEA92600"><gtr:id>5EE3B711-DED5-4EB0-AC1A-EE27FEA92600</gtr:id><gtr:name>ParAid Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8962CB0C-168F-4290-8932-3130253FB14F"><gtr:id>8962CB0C-168F-4290-8932-3130253FB14F</gtr:id><gtr:name>Brain in Hand Ltd</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EED55AEE-EE68-4B5D-BB08-C4F173080300"><gtr:id>EED55AEE-EE68-4B5D-BB08-C4F173080300</gtr:id><gtr:name>Alliance Boots</gtr:name><gtr:address><gtr:line1>D122 Records Centre</gtr:line1><gtr:postCode>NG90 4XY</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/00EC857A-A759-4CBA-B69D-4699F33CBC26"><gtr:id>00EC857A-A759-4CBA-B69D-4699F33CBC26</gtr:id><gtr:name>Oxtex Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3CFB9490-9508-4E43-A019-042327F992A7"><gtr:id>3CFB9490-9508-4E43-A019-042327F992A7</gtr:id><gtr:name>Eisai Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E7A3C64A-4899-4B20-ABFA-E49DC0E6441E"><gtr:id>E7A3C64A-4899-4B20-ABFA-E49DC0E6441E</gtr:id><gtr:name>Sygnature Discovery Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4A53D269-02C1-473C-BEB5-28B220F178AF"><gtr:id>4A53D269-02C1-473C-BEB5-28B220F178AF</gtr:id><gtr:name>Crown Bioscience Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A621CD6-4DE9-4B35-992C-631871D7793E"><gtr:id>8A621CD6-4DE9-4B35-992C-631871D7793E</gtr:id><gtr:name>University of Rochester</gtr:name><gtr:address><gtr:line1>PO Box 270001</gtr:line1><gtr:line4>Rochester</gtr:line4><gtr:line5>New York</gtr:line5><gtr:postCode>NY 14627</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE3B711-DED5-4EB0-AC1A-EE27FEA92600"><gtr:id>5EE3B711-DED5-4EB0-AC1A-EE27FEA92600</gtr:id><gtr:name>ParAid Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8962CB0C-168F-4290-8932-3130253FB14F"><gtr:id>8962CB0C-168F-4290-8932-3130253FB14F</gtr:id><gtr:name>Brain in Hand Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2C8CD331-4C2E-499A-AFD3-3A16680EBC93"><gtr:id>2C8CD331-4C2E-499A-AFD3-3A16680EBC93</gtr:id><gtr:name>SimPore Inc</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318"><gtr:id>5B71FE8A-DC4E-41C4-81D2-E6D6A7AA0318</gtr:id><gtr:name>Astex Pharmaceuticals</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/96BFFAB5-69B1-49E8-8F41-9C763818EFA6"><gtr:id>96BFFAB5-69B1-49E8-8F41-9C763818EFA6</gtr:id><gtr:name>Jaguar Land Rover</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/9BD7D307-E32D-4790-8E26-C85C183950DA"><gtr:id>9BD7D307-E32D-4790-8E26-C85C183950DA</gtr:id><gtr:firstName>Susan</gtr:firstName><gtr:surname>Huxtable</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_14121"><gtr:id>CAE58972-74EF-446D-AB35-D3C20F57ADAF</gtr:id><gtr:title>Proximity to Discovery 2014 ? University of Nottingham</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_14121</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The MRC Proximity to Discovery scheme awards universities funds to help develop new collaborations, and ways of exchanging knowledge and skills.&amp;nbsp; The awards can be used to support activities that promote the value of academic-industry partnership, and enhance academic and industry researchers? understanding of each other?s needs and capabilities.&amp;nbsp; This may be through people exchanges, creation of technology demonstrators, showcase events, commercialisation workshops and ?entrepreneurs in residence? schemes.&amp;nbsp; Such exchanges of knowledge and skills will boost the most fruitful collaborations between UK universities and life science companies.</gtr:technicalSummary><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>220000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Rochester</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>University of Rochester Medical Centre</gtr:department><gtr:description>Dr Kevin Webb: Commercialisation of next-generation erasable flow-through biosensors</gtr:description><gtr:id>153E873E-C2E4-4526-8822-C3F1FA79B18A</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>58b44b0ddf5588.79619432-2</gtr:outcomeId><gtr:partnerContribution>Benchmark known SERS performance against leading prior art - cost and performance</gtr:partnerContribution><gtr:piContribution>Demonstration of utility of SERS for applications for intrinsic evaluation of Raman spectra of:
o Proteins
o Small molecules
o Lipids
o Nucleic Acids
o Nano-particles
o Exemplification in different bio-matrices (Blood, saliva, urine etc)</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Dr Tom McNally: Inhibitors for Fibrotic Diseases - People Exchange Programme to Progress Early Leads and Enable Applications for More Substantial Funding</gtr:description><gtr:id>0A221B98-DF4C-40BB-88E7-849812F47FDD</gtr:id><gtr:impact>No outputs yet, a patent filing by the University of Nottingham is anticipated.</gtr:impact><gtr:outcomeId>56caf1e569fdb7.67930257-1</gtr:outcomeId><gtr:partnerContribution>Assays, computer modelling and medicinal chemistry.</gtr:partnerContribution><gtr:piContribution>Identification of a small molecule inhibitor for the treatment of idiopathic pulmonary fibrosis.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>ParAid Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dr Don Sharkey: Neonatal Inter-Hospital Transport System</gtr:description><gtr:id>2FE1B75B-CC97-40C2-B81F-B7B8492C548F</gtr:id><gtr:impact>No outcomes yet; anticipated registering of design rights, plus patent filings and publications.</gtr:impact><gtr:outcomeId>56caf34f62dce6.80208908-1</gtr:outcomeId><gtr:partnerContribution>Computer design, further developmental design input and regulatory affairs.</gtr:partnerContribution><gtr:piContribution>Design of a novel neonatal transport system, to reduce noise and vibration in addition to more secure transport.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Sygnature Discovery Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dr Ian Todd: Reuse and refinement of anti-microbials as anti-inflammatories for therapy of orphan autoinflammatory diseases.</gtr:description><gtr:id>1DABEEB9-1229-4F2B-B87F-5CF5A64A7F69</gtr:id><gtr:impact>No outputs to date.</gtr:impact><gtr:outcomeId>56caf5477b0353.77358681-1</gtr:outcomeId><gtr:partnerContribution>Identification of additional chemical structures of interest for screening by University of Nottingham, built models of potency for each compound cluster, Bayesian modelling and 3-D predictions</gtr:partnerContribution><gtr:piContribution>Performance of a multiplexed signalling molecule detection methodology as a platform for drug repurposing and refinement, which has led to identification of a number of lead compounds.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Alliance Boots</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>Dr David Scurr: Active Compound Delivery into the Skin - Industrial Partners Engagement</gtr:description><gtr:id>DD167BFB-F9AA-463C-BFB8-AF463805FE6A</gtr:id><gtr:impact>27010630</gtr:impact><gtr:outcomeId>58b41c70822676.65068442-1</gtr:outcomeId><gtr:partnerContribution>Alliance Boots PLC have provided knowledge and skills in topical delivery.</gtr:partnerContribution><gtr:piContribution>Research activities within the School of Pharmacy have led to the development of spectrometry based methodologies which can be used to probe the extent of active pharmaceutical and / or cosmetic agents into skin tissue.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Crown Bioscience Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Prof Lindy Durrant: Crown Bioscience Exchange: pre-clinical models</gtr:description><gtr:id>5E0B4B79-32BE-4B7E-8DF0-CF9A38694FC9</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>58b4120633eca6.20141613-1</gtr:outcomeId><gtr:partnerContribution>Expertise with screening and testing of functionality and likely immunogenicity.</gtr:partnerContribution><gtr:piContribution>Generation of a panel of therapeutic monoclonal antibodies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>SimPore Inc</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Dr Kevin Webb: Commercialisation of next-generation erasable flow-through biosensors</gtr:description><gtr:id>09AA98F3-4240-4D60-86C4-1F49AE126DAA</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>58b44b0ddf5588.79619432-1</gtr:outcomeId><gtr:partnerContribution>Benchmark known SERS performance against leading prior art - cost and performance</gtr:partnerContribution><gtr:piContribution>Demonstration of utility of SERS for applications for intrinsic evaluation of Raman spectra of:
o Proteins
o Small molecules
o Lipids
o Nucleic Acids
o Nano-particles
o Exemplification in different bio-matrices (Blood, saliva, urine etc)</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Astex Pharmaceuticals</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Astex Therapeutics Ltd</gtr:department><gtr:description>Dr Marie-Christine Pardon: Thymosin beta 4: a potential candidate drug for Alzheimer's disease and vascular dementia</gtr:description><gtr:id>ABAFD388-88F0-45B9-8721-2EF96FA09CE6</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>58b41835652d22.82707305-2</gtr:outcomeId><gtr:partnerContribution>Knowledge related to therapeutic peptide development</gtr:partnerContribution><gtr:piContribution>Identification of a novel potential disease mechanism for Alzheimer's disease
- Improved understanding of the role of TB4 in immune cell function
- Increased confidence in the suitability of TB4 as therapeutic target for Alzheimer's disease</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eisai Ltd</gtr:collaboratingOrganisation><gtr:country>Japan</gtr:country><gtr:description>Dr Marie-Christine Pardon: Thymosin beta 4: a potential candidate drug for Alzheimer's disease and vascular dementia</gtr:description><gtr:id>90FA13C3-7B23-41E3-A0FB-DAAE22371542</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>58b41835652d22.82707305-1</gtr:outcomeId><gtr:partnerContribution>Knowledge related to therapeutic peptide development</gtr:partnerContribution><gtr:piContribution>Identification of a novel potential disease mechanism for Alzheimer's disease
- Improved understanding of the role of TB4 in immune cell function
- Increased confidence in the suitability of TB4 as therapeutic target for Alzheimer's disease</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oxtex Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Prof David Gardner: Minimally Invasive Cloacal Repair Operation (MICRO)</gtr:description><gtr:id>6368AD55-B8CF-4E45-9F2B-C5E36B9B983B</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>58b414ff756867.04199399-1</gtr:outcomeId><gtr:partnerContribution>The tissue engineering and development of anisotrophic tissue expanders was conducted by Oxtex Ltd, Witney, UK</gtr:partnerContribution><gtr:piContribution>Investigation of a unique treatment options for cloaca; the defect is one of the most formidable technical challenges in pediatric surgery. A pilot study using available cadaveric material will establish the surgical techniques and efficacy of implantation of tissue expanders into the ano-genital sinus of a pig.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Brain in Hand Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dr Kate Radford: Evaluation of the Brain in Hand software for use with people with acquired brain injuries (ABI)</gtr:description><gtr:id>A7718AFC-F065-4204-83ED-088B26142A2A</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>58b41a937eb7c3.22410542-1</gtr:outcomeId><gtr:partnerContribution>? Facilitation of User and Professional technical workshops (these will be held at least 3 times during the study programme to ensure that user and professional views about BiH software development are factored in to the overall design). Glenn Atter (Technical Director) and Heather Cook (Client Director) along with other members of the BiH team will facilitate these workshops
? Development and implementation of marketing and PR campaign, promoting the collaboration between University of Nottingham and Brain in Hand to foster the development of BiH into the ABI rehabilitation pathway.</gtr:partnerContribution><gtr:piContribution>? Undertake some early stakeholder engagement activity in partnership with Brain in Hand to inform the necessary technological developments for bid development and evaluation as part of the existing project.
? Explore the potential for widening the market for Brain in Hand's application in other conditions such as children with ABI and adults with MS and dementia;
? Identify and engage with relevant networks and showcase our research at UoN, thereby acting as a catalyst for further networking and collaboration.
? Provide an opportunity for an experienced post-doctoral researcher to assist in bid writing, while developing their potential to become an independent researcher.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Jaguar Land Rover</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Dr Don Sharkey: Neonatal Inter-Hospital Transport System</gtr:description><gtr:id>291A5491-3653-403D-AA13-4125B940FD5C</gtr:id><gtr:impact>No outcomes yet; anticipated registering of design rights, plus patent filings and publications.</gtr:impact><gtr:outcomeId>56caf34f62dce6.80208908-2</gtr:outcomeId><gtr:partnerContribution>Computer design, further developmental design input and regulatory affairs.</gtr:partnerContribution><gtr:piContribution>Design of a novel neonatal transport system, to reduce noise and vibration in addition to more secure transport.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Faculty of Medicine and Health Sciences Showcase</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>265EAFE4-E83E-4D7C-9E24-558D9E261283</gtr:id><gtr:impact>In July 2016 we hosted a Transformative Technologies Research Showcase, attended by academic colleagues, industrial collaborators, prospective industrial partners, charities,
policy makers and funders and where we showcased the Clinical Translational Research undertaken at Nottingham. Intended to kick-start new industrial relationships and to provide a space for academic colleagues to come together and prompt new cross faculty, multi-disciplinary collaborations, the event was hosted by Professor Jonathan Ball, Director of Research, Faculty of Medicine &amp;amp; Health Sciences and was an opportunity for delegates to find out about some of the world leading technologies
developed out of Nottingham. They also had the opportunity to see some of them in our pop-up Faculty of Medicine and Health Sciences Technology Demonstrator. A programme of speakers covered a range of topics from both industry and academic perspective. The event was held in the University of
Nottingham Medical School, and was attended by around 100 delegates - 36 industry guests and 62 internal, cross-faculty guests.</gtr:impact><gtr:outcomeId>58b44d8b7b3098.94792064</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E4B8F291-A7B6-48C3-BF57-C2A0406C79D1</gtr:id><gtr:title>Passing on the medicinal chemistry baton: training undergraduates to be industry-ready through research projects between the University of Nottingham and GlaxoSmithKline.</gtr:title><gtr:parentPublicationTitle>Drug discovery today</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b265804c5af2b4d93dbd440ca8c86bc3"><gtr:id>b265804c5af2b4d93dbd440ca8c86bc3</gtr:id><gtr:otherNames>Macdonald SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1359-6446</gtr:issn><gtr:outcomeId>5a8befc97b0af0.72080082</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3953BBAF-1E65-40D9-AF2B-E8E768D542B1</gtr:id><gtr:title>Age-Related Changes to Human Stratum Corneum Lipids Detected Using Time-of-Flight Secondary Ion Mass Spectrometry Following in Vivo Sampling.</gtr:title><gtr:parentPublicationTitle>Analytical chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ec77c5c2cde411fd1ee771b6d110b746"><gtr:id>ec77c5c2cde411fd1ee771b6d110b746</gtr:id><gtr:otherNames>Starr NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0003-2700</gtr:issn><gtr:outcomeId>58b41d83bcb169.74173845</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3D92AF2-4087-4747-9EE0-DF22A9F6CC6C</gtr:id><gtr:title>Unusual Undergraduate Training in Medicinal Chemistry in Collaboration between Academia and Industry.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f6ce806df0a9067081218e8901fb9b73"><gtr:id>f6ce806df0a9067081218e8901fb9b73</gtr:id><gtr:otherNames>McInally T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>5a8bef20cc3748.40080131</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B9EB1572-163C-42E9-83F9-934D853EF151</gtr:id><gtr:title>A signalome screening approach in the autoinflammatory disease TNF receptor associated periodic syndrome (TRAPS) highlights the anti-inflammatory properties of drugs for repurposing.</gtr:title><gtr:parentPublicationTitle>Pharmacological research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dbdd8d23ec658f39ddcc4fbe4d6fe83f"><gtr:id>dbdd8d23ec658f39ddcc4fbe4d6fe83f</gtr:id><gtr:otherNames>Todd I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1043-6618</gtr:issn><gtr:outcomeId>5a8becf9289980.80853731</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_14121</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>